Home › Triple-Negative Breast Cancer › Pennsylvania
Triple-Negative Breast Cancer clinical trials in Pennsylvania
23 studies for Triple-Negative Breast Cancer are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Sep 28, 2026 · NCT06586957Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Sidney Kimmel Cancer Center at Jefferson ( Site 0049), Philadelphia
- Cancer Care Associates Of York ( Site 9517), York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06393374Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Recruiting
Ages 30 and older · Women · Updated Sep 25, 2026 · NCT02945579Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07340541A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- UPMC, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07020117The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- WellSpan York Cancer Center, York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT03606967Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Lancaster General Health, Lancaster
- University of Pennsylvania Abramson Cancer Center, Philadelphia
- UPMC Magee-Womens Hospital, Pittsburgh
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05633654A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07029399A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07115043A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Lehigh Valley Health Network, Allentown
- Abramson Cancer Center of The University of Pennsylvania, Philadelphia
- Local Institution - 0360, Pittsburgh
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06926868Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Alliance Cancer Specialist, Doylestown
- Allegheny Health Network, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Pennsylvania (U Penn), Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT01042379Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 4, 2026 · NCT04434040ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
- UPMC Hillman Cancer, Pittsburgh
RecruitingObservational study
Ages 18 and older · Women · Updated May 1, 2026 · NCT07332975Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 29, 2026 · NCT04468061Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
- Lehigh Valley Health Network, Allentown
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 27, 2026 · NCT03808337Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
- Thomas Jefferson University Hospital, Philadelphia
Recruiting
Ages 40 and older · All sexes · Updated Jan 23, 2026 · NCT04959474Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 29, 2025 · NCT06249048Role of the Immune Environment in Response to Therapy in Breast Cancer
- Abramson Cancer Center, Philadelphia
RecruitingObservational study
Ages 18 and older · Women · Updated Jul 8, 2025 · NCT05396612CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Cancer Care Associates of York, York
RecruitingObservational study
Ages 18 and older · Women · Updated Jan 7, 2025 · NCT06230185From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.